In Brazil Market for Breast Cancer Drugs to Grow 40% in 4 Years

Cancer treatment The breast cancer drug market in Brazil will grow from US$ 424 million in 2009 to US$ 611 million in 2014, says Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues.

Factors promoting the market’s growth include steady increases in the number of incident breast cancer cases, shifts toward higher-cost chemotherapy and hormonal regimens in the adjuvant setting and increases in the use of targeted therapies following novel product launches and label extensions.

“The value of the Brazilian breast cancer drug market in 2009 (US$ 424 million) rivals those in some major pharmaceutical markets like United Kingdom and Japan and greatly exceeds breast cancer drug sales in other emerging markets (China, India, Russia),” stated Decision Resources’ Therapeutic Area Director Kate Hohenberg.

“A well-established public healthcare system that pays the cost of drug therapy for eligible patients and a small but lucrative pool of privately insured patients support Brazil’s sizeable breast cancer drug  market.”

The new Emerging Markets report entitled Breast Cancer in Brazil also finds that given the drawbacks and limitations of current treatments and Brazilian physicians’ enthusiasm for novel approaches in hard-to-treat patient segments (e.g., triple-negative breast cancer), emerging breast cancer therapies will be well received in Brazil.

Two novel agents – Roche’s trastuzumab-DM1 and Sanofi-Aventis’s BSI-201 – are expected to launch in Brazil towards the end of 2014.

“By the end of our five-year forecast period (2009-2014), we expect two novel breast cancer agents to launch in Brazil – Roche’s trastuzumab-DM1 and Sanofi-Aventis’s BSI-201. These launches will be facilitated by the low regulatory hurdle (additional domestic clinical trials are not required) and physicians’ receptivity to new therapies for underserved segments of the breast cancer market,” added Ms. Hohenberg.

The new reports features extensive primary research of physicians and epidemiology study, with analysis of trends in major Brazilian cities – Rio de Janeiro, São Paulo, Brasília, Belo Horizonte, Curitiba and Salvador – and the country overall.

Tags:

You May Also Like

Brazil’s Lula Calls for Urgent Meeting to Discuss Bolivia’s Oil Nationalization

Brazilian President Luiz Inácio Lula da Silva has scheduled a meeting this Tuesday, May ...

Brazil Lula’s Brother: ‘Dad Would Pull His Ear for Lying’

Brazil’s orthodox Finance Minister Antonio Palocci was linked to the corruption scandal of the ...

Rousseff and Serra Hide Their Pro Choice Leaning to Win Brazil Presidency

Dilma Rousseff, the woman handpicked by Brazilian president Luiz Inácio Lula da Silva to ...

Requiem for a Bubble

Globo Group and the Folha Group, two giants of the media, who had wrangled ...

Brazil to Fund Research on Hantavirus

Brazil’s Ministry of Health and the National Scientific and Technological Development Council (CNPq) will ...

IMF Goes to Brazil to Liquidate the Country’s Debt

The managing director of the International Monetary Fund, Rodrigo de Rato, will be in ...

Brazilian Congress Passes 2006 Budget After Government Caves In

Almost four months late, last night a joint session of the Brazilian Congress approved ...

Despite Cheaper Food, Inflation Up in Brazil

Inflation in Brazil resumed an upward trend in October. October’s Broad National Consumer Price ...

Alexandria’s Pope Visits Brazil to Consecrate First Coptic Church

Pope Shenouda III of Alexandria will make his first visit to Brazil in February. ...

Brazil Accuses EU of Moving Backwards on WTO Agreement

In a press conference Tuesday, January 24, Brazil’s Minister of Foreign Relations, Celso Amorim, ...